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Increased risk of environmentally induced cancer is associated with various types of exposures
and host factors, including differences in carcinogen metabolism. Since many carcinogenic
compounds require metabolic activation to enable them to react with cellular macromolecules,
individual features of carcinogen metabolism may play an essential role in the development of
environmental cancer. In this context, cigarette smoking has often been the main type of
carcinogenic exposure examined in human studies. Increasing attention has recently been paid to
the dose level at which individual susceptibility may be observed. Present studies on increased
risk of smoking-related lung cancer associated with phenotypic or genotypic variation of the
genes encoding for CYPlAl or CYP2D6 enzymes are summarized. Similarly, higher risks of lung
or bladder cancer seen at various levels of smoking in association with polymorphism of the
glutathione S-transferase gene GSTM1 or NAT1 and NAT2 genes involved in N-acetylation are
reviewed. Finally, the influence of CYP2E1, GSTM1, or the combined at-risk genotype on the
risk of hepatocellular carcinoma in smokers is briefly discussed. Environ Health Perspect
105(Suppl 4):749-754 (1997)
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Introduction
Increased risk ofcancer and other environ-
mentally induced diseases is associated with
various types ofexposures and host factors,
including differences in carcinogen metab-
olism. Since many carcinogenic com-
pounds require metabolic activation before
they can react with cellular macromole-
cules, individual features of carcinogen
metabolism may play an essential role in
the development of environmental cancer
(1). Many compounds are converted to
reactive electrophilic metabolites by the
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oxidative, mainly cytochrome P450-related
enzymes (CYPs). Secondary metabolism,
mainly involving epoxide hydrolase and
another subset ofactivating CYP isoforms,
leads to the formation of the highly reac-
tive metabolites that can bind to genomic
DNA (2). Other enzyme systems, e.g., many
transferases such as glutathione S-trans-
ferases, UDP-glucuronosyltransferases, sul-
fotransferases, and acetyltransferases, take
part in detoxification ofoxidated forms of
carcinogens. Thus, the concerted action of
these enzymes may be crucial in determin-
ing the final biological effect(s) ofa xenobi-
otic chemical. A number of genes that
encode carcinogen-metabolizing enzymes is
presently known. Individual variation in
enzymes activating or detoxifying carcino-
gens and other xenobiotics have subse-
quently been related to discovered genetic
polymorphisms for these genes (1).
Recently, increasing attention has been
paid to the dose level ofexposure at which
individual susceptibility may be observed
(3). In this context, cigarette smoking is the
main type of carcinogenic exposure exam-
ined in many human studies. Although it
is well known that the risks for tobacco-
related cancers increase with increased
smoking (4) and that the composition and
filter type of cigarettes modifies the risk
(4), few studies have focused on possible
dose dependence ofcancer susceptibility.
The possible role of genetic factors in
the regulation of the dose-response rela-
tionship after exposure to carcinogens has
been seen in animal studies. A difference
related to genotype in formation of
2-aminofluorene-hemoglobin adducts was
found in hamsters between slow and rapid
acetylators; adduct formation increased
more with dose in slow than in rapid
acetylators (5). Similarly, formation of
4-aminobiphenyl-DNA adducts in mice
was increased with dose in the liver and
urinary bladder, but the effect appeared to
be sex- and organ-specific (6).
Pulmonary Carcinogenesis
Inducibility ofCYPlA-related phenotypic
activity can be regarded as an indirect quan-
titative measurement of effects related to
dose and host factors. In the lungs an impli-
cation of this is the decreased level of
inducibility found in lung cancer dependent
on the time period patients refrained from
smoking, while in noncancer patients no
cigarette smoke-related inducibility could be
demonstrated (7). Inducibility of CYPIAJ
phenotype was first demonstrated by
Kellermann et al. (8) to be higher in lung
cancer patients than in controls. This associ-
ation has also been shown using CYPIAI
activity in cryopreserved lymphocyte as the
marker (9). Since these studies, association
of CYPIAJ genotype with inducibility and
lung cancer risk has been extensively stud-
ied (10-19). Anttila et al. (20) demon-
strated the presence ofCYPlAl isozyme in
the lung tissue ofsmokers with peripheral
lung cancer. In the Japanese population,
associations between risk oflung cancer and
certain CYPIAI alleles have been demon-
strated in smokers (14-16); the association
has not been confirmed in Caucasian popu-
lations, probably due to more infrequent
occurrence ofthe at-risk allele in Caucasians
(17,18,21,22). Possible dose dependence of
CYPlAl-associated metabolic susceptibility
has not been much examined. One of the
first reports was a Japanese study (23) that
observed that patients with the at-risk MspI
CYPIAI genotype (m2m2) contracted
cancer after fewer cigarettes (mean lifetime
consumption 31 ± 12x 104 cigarettes) than
those with other genotypes (mean lifetime
consumption 43± 18 x 104 cigarettes).
The individuals with the susceptible
genotype were then found to have a high
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risk (OR7.3, 95% CI 2.1-25) at alowdose
level and the difference in susceptibility
between the genotypes was reduced at high
dose levels (23). In a later report (24), the
finding ofincreased lung cancer risk associ-
ated with the MspI CYPlAI susceptible
genotype was confirmed; an excess risk was
seen particularly in light smokers (less than
30x 104 cigarettes over lifetime) with squa-
mous cell carcinoma as contrasted to those
who had smoked more. In adenocarcinoma,
no such relationship was found (Table 1). A
recent study amongAfrican Americans (25)
observed no overall association between
lung cancer and a rare race-specific CYPIAI
polymorphism, although a slightly increased
but nonsignificant risk was associated with
the presence ofthe variant CYPJAl allele at
higher smoking level (1-35 pack-years, OR
1.3, 95% CI 0.6-3.2; >35, OR 2.2, 95%
CI 0.6-7.8). Taken together these results
appear to emphasize the influence ofdiffer-
ent allele frequencies in different human
populations on riskexperienced.
In genotyping studies using polymerase
chain reaction assays (26,27), a tendency
for an association between the GSTMI
genotype and squamous cell carcinoma has
been reported (26,28,29). A Japanese
study combining the risk genotypes for
CYPIAI and glutathione S-transferase 1
(GSTMI) demonstrated an enhanced risk
oflung cancer 30). Patients with the at-
risk MspI or Ile-Valgenotypes of CYPIAI
contracted lung cancer after smoking fewer
cigarettes than those with the other
CYPIAI genotypes. In combined geno-
typing, the individuals with the susceptible
Table 1. CYPlA1 (Mspl) genotype and exposure to
cigarette smoke.
CYPlA1 genotype, %
Cancertype mlml mlm2 m2m2
Adenocarcinoma
(n=41)
0 34 21 4
<30 26 57 17
>30 42 47 11
Total 35 53 13
Squamous cell carcinoma
(n=78)
0 100 0 0
<30 28 38 34
>30 44 44 12
Total 40 40 21
All patients
(n=250) 36 47 16
Historical healthy controls
(n= 166) 44 45 11
The number of cigarettes given refers to the amount
consumed over a lifetime smoking (x104). Modified
from Okada etal. (24).
genotype of CYPIAI (MspI) and the
GSTMI null genotype were at a high risk
with an odds ratio of16.0 (95% CI 3.8-68)
at the lower cumulative cigarette dose level
(32x 104 cigarettes over lifetime) as com-
pared to those with the other CYPlAI
genotypes and GSTMI+ genotype. The
risk estimate for the combined Val-Val
CYPIAI and GSTMI null genotype was
even higher (OR 41, 95% CI 8.7-193) at
the lower dose level (30). Similarly in
another study, the GSTMI null genotype
was associated with an overall increased
lung cancer risk (OR 1.87) (31). The
study found a higher risk at the highest
cumulative dose ofcigarette smoke expo-
sure in squamous cell carcinoma patients
with GSTMI null genotype; the odds ratio
however, remained nonsignificant or at
borderline significance (Table 2).
Association between some ofthe bio-
markers related to initiation ofcarcinogene-
sis and susceptible genotypes has been
noticed. Formation of smoking-related
DNA adducts in human lung tissue can be
used as a marker of internal dose, and
smokers are known to have significantlyele-
vated levels of aromatic and/or hydro-
phobic adducts compared with nonsmokers
(32,33). In recent studies, up to 6-fold
increase in the amount ofpulmonary DNA
adducts has been found in smokers as com-
pared to ex-smokers or nonsmokers, with a
tendency of GSTMJ null genotype individ-
uals to have higher levels ofadducts than
thosewith atleast one allele present (34).
Several studies have suggested that the
capability to metabolize debrisoquine (a
test drug) extensively (extensive metabolizers,
EM) is associated with increased risk of
lung cancer, as compared to poor metabo-
lizers (PM) (35). A weak association
between CYP2D6genotype predictive of
the EM phenotype and increased risk of
lung cancer has since been reported by
some studies, but other studies found no
association (36-41). Recently, a positive
association between the frequency ofpoor
metabolizers and the risk of adenocarci-
noma ofthe lungs was published (42). The
association of PM genotype of CYP2D6
with increased risk oflung adenocarcinoma
was speculated to be due to metabolic
activity by this isozyme, a tobacco-specific
nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK), as also sug-
gested by others (43). Present evidence for
interaction between the risk related to
CYP2D6genotype/phenotype and the
extent ofsmoking is difficult to evaluate
because most studies lack quantitative data
on smoking. Bouchardyet al. (44) observed
an increased riskoflung cancerforextensive
metabolizers. The excess risk in EMs was
dependent on the level ofsmoking, while in
individuals who were poor or intermediate
metabolizers, no such increase was found
even athigh level ofsmoking (Table 3). The
increased risk (OR 4.95) in extensive
metabolizers became evident at the tobacco
consumption level of >30 g/day as com-
pared to smokers who consumed <20 g/day.
This was again speculated to be associated
with the increasing levels of metabolites
of the tobacco-specific carcinogen NNK
present in extensive metabolizers (44).
Occupational exposure to asbestos
increases the risk of lung cancer and
mesothelioma. Indications ofincreased risk
ofasbestos-related mesothelioma and other
pulmonary disorders have been obtained
recently. Both GSTMI and NAT2 (N-
acetylation) genotypes were associated with
malignant mesothelioma in workers who
were highly exposed to asbestos (45).
In another study, GSTMI null genotype
was found to be related to risk ofasbestosis
(pulmonary fibrosis) among workers
exposed to high levels of asbestos (46),
whereas no association between radiograph-
ical or lung function changes and GSTMI
genotype was seen in a group ofasbestos
workers with mostly low or moderate
exposure (47). Glutathione S-transferase
Table 2. Association of GSTM1 null genotype and cumulative lifetime smoking in lung cancer patients by tumor
histology.a
Smoking, pack-years
<40 40-60 >60
Type of cancer OR 95%CI OR 95%CI OR 95%CI
Squamous cell carcinoma 1.22 0.36-4.14 1.49 0.53-4.22 3.18 0.98-10.9
(7)b (11) (13)
Small cell carcinoma 0.87 0.23-3.26 2.44 0.72-8.73 3.66 0.64-27.3
(5) (19) (6)
Adenocarcinoma 1.32 0.54-3.24 1.49 0.53-4.22 1.22 0.33-4.55
(14) (11) (6)
Abbreviations: OR, odds ratio; Cl, confidence interval. 'Modified from Kihara et al. (31). bNumber of cases studied
in parentheses.
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Table 3. CYP2D6phenotypes and dailytobacco consumption in lung cancer patients.a
Phenotypic CYP2D6classification
Tobacco consumption, Low Medium Hig
g/day OR 95% Cl OR 95% Cl OR
<20 1.0 1.0 1.0
(26/17)b (17/20) (15/30)
21-30 0.43 0.14-0.37 1.04 0.30-3.60 1.43
(8/16) (10/20) (17/10)
>30 0.40 0.13-1.15 0.43 0.14-1.34 4.95
(12/18) (10/20) (17/10)
Abbreviations: OR, odds ratio; Cl, confidence interval. "Modified from Bouchardy et al. (44). bNumbe
studied in parentheses (cases/controls).
Table 4. Effect of NAT2acetylator phenotype on the level of aminobiphenyl-hemoglobin adducts
levels ofcigarette smoke exposure.a
Urinary nicotine+cotinine, NAT2acetylator phenotype
pmol/mmol creatinine Rapid, ABP-Hb, pg/g Hb Slow, ABP-Hb, pg/g Hb % Increas
0 13 27
(n=44)b
52
92
99
132
>2.5 128 119
(n= 19)
Modified from Vineis et al. (51). "Determined by urinary nicotine + cotinine concentration. bNumber
studied in parentheses.
isozymes take part in reactions detoxifying
reactive oxygen species (48), known to be
generated by asbestos exposure and smok-
ing. The excess risk associated with GSTMI
null genotype in the asbestos-exposed
patients in these studies appeared, however,
to be exerted at a high level of exposure
only. The possible mechanistic role ofN-
acetylation genotype in modifying risk for
asbestos-related malignant mesothelioma is
more difficult to see.
Bladder Carcinogens
and Bladder Cancer
Malaveille et al. (49) found adose-dependent
relationship between urinary mutagenicity,
amount of thioethers, and the number of
cigarettes smoked per day as well as the
amount of nicotine and cotinine in urine.
Furthermore, the mutagenicity was nearly
twice as high in dose-corrected black
tobacco smokers than in blond tobacco
smokers. Bartsch et al. (50) showed a dose-
dependence of ABP aminobiphenyl-
hemoglobin (ABP-H6) adducts and the
concentration of cotinine + nicotinine in
urine, but no clear-cut quantitative associa-
tion could be shown between the amount
of adducts and the amount of smoking.
Later, a dose-dependent increase in
ABP-Hb adducts was demonstrated (51).
Furthermore, the amount ofad(
higher in slow than in rapid N-a
(determined both genotypically
notypically) at low dose levels (
by urinary cotinine + nicotine le
at higher dose levels the differeni
to level off (Table 4). The diff
acetylation phenotype was also re
the presence of DNA adducts t
biphenyl metabolites in urothe
and the amount ofadducts incre
increasing urinary mutagenicity.
within the same genotype no cc
between the acetylation rate as a
caffeine metabolites was found (5
Aspects related to dose might I
tant in evaluating the postulated
tion of bladder cancer risk by r
polymorphisms, e.g., those for
GSTM1 (52-56). In the study
al. (57), an increase in risk o0
cancer was found for patients
GSTM1 null genotype than for t
were homozygous or heterozygoi
GSTMI wild-type allele. No si
relationship with dose could
although some difference betweer
levels was observed (< 50 pack
>50 pack-years; Table 5). Brock
al. (58), who found an overall
increased risk ofbladder cancer
Ih
95% Cl
0.42-4.85
1.61-15.23
-r _a ; +
Table 5. GSTM1 genotype and cumulative dose of
smoke in bladder cancerpatients.a
Smoke dose, GSTM1+ GSTM1 null
pack-years OR OR
Belletal.(57)
Nonsmokers 1 1.3 (38/81)b
Smokers (175/118)
1-50 2.2 4.3
>50 3.5 5.9
Brockmoller et al. (58) ,, UI SUUJBUls Nonsmokers 1.96 (93/47)
Smokers
1-20 1.35 (64/99)
20-50 1.35 (97/199)
at different >50 0.74 (44/49)
Overall 1.33 (95% Cl
0.94-1.87)
3e in adducts Abbreviations: OR; odds ratio, Cl, confidence interval.
107 aModified from Bell et al. (57) and Brockmoller et al.
(58). bNumber of subjects studied (cases/controls) in
90 parentheses.
43 with GSTMI null genotype, did not find
dependence ofthe risk on increasing amount
-7 ofsmoking; in contrast, the risk appeared to
be associated with lower dose level. In keep-
r of subjects ing with other studies, both NATI and
NAT2 enzymes catalyze the activation (0-
acetylation) and inactivation (N-acetylation)
ofarylamine carcinogens. Polymorphism in
ducts was acetylation rate was first associated with
cetylators NAT2 genelocus, NAT2(59). In astudyon
and phe- occupational exposure to bladder carcino-
as judged gens, low acetylation rate was observed to
vels), but offer moderate protection from bladder
Lce tended cancer in benzidine-exposed workers (54).
erence in Cigarette smoking appeared to influence the
.flected in risk, with a somewhat higher estimate for
:o amino- higher level ofsmoking (<20 pack-years,
lial cells, OR 1.4;>20 pack-years, OR 1.6).
-ased with asedwithOtherMalignancies However,
Drrelation Risk ofhepatocellular carcinoma (HCC)
ssayed by was studied in a Taiwanese population,
1). most ofwhom were also positive for hepati-
be impor- tis-B antigen (60). In this study, the signifi-
modifica- cance ofcytochrome P450E and GSTMI
metabolic genotypes was examined. An increase in
NAT2 or the HCC risk was reported to occur
by Bell et depending on the dose ofcigarette smoke
f bladder exposure in patients who were homozygous
with the for the cl allele (cllcl) of the CYP2EI
those who gene. No association with GSTMI null
us for the genotype was found (Tables 6, 7). Defective
ignificant alleles of the CYP2D6gene may also be
be seen, involved in increased risk ofliver cancer;
smoking subjects having functional gene (extensive
-years vs. metabolizer genotypes) seemed to have 6.4-
m6ller et fold higher risk ofprimary liver cancer than
1.40-fold those who had defective alleles (61).
associated Possible hepatocarcinogens involved in or
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(n=25)
1.5-2.4
(n=9)
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Table 6. CYP2E1 (Pstl) and GSTM1 at-risk genotypes in hepatocellular carcinoma
patients by cumulative lifetime smoking.a
Smoking, CYP2E1cl/cl GSTM1 null
pack-years OR 95%CI OR 95% Cl
Nonsmokers 1.0(12/66)1 1.0 (10/61)
Smokers
1-17.4 1.8 (5/15) 0.6-6.0 1.1 (3/16) 0.3-4.7
17.5-29.2 3.1 (4/7) 0.8-12.4 0.8 (1/8) 0.1-6.8
>29.2 3.7 (4/6) 0.9-15.0 1.2 (2/10) 0.2-6.4
Abbreviations: OR, odds ratio; Cl, confidence interval. aModified from Yu etal. (60). bNumber ofcases in parentheses.
Table 7. CYP2E1 (Pstl) at-risk genotype, alcohol consumption and cigarette smoking in hepatocellular carcinoma
patientsa.
Cigarette Subjects studied,
Alcohol smoking CYP2E1 cl/cl OR 95% Cl cases/controls
No No No 1.0 5/55
No No Yes 2.1 (0.7-6.4) 11/58
Yes No Yes 1.4 (0.1-13.3) 1/8
No Yes Yes 3.9 (1.1-13.5) 7/20
Yes Yes Yes 7.3 (1.8-29.2) 6/9
Abbreviations: OR, odds ratio; Cl, confidence interval. aModified from Yu et al. (60).
Table 8. GSTM1 genotype and smoking status in patients with colorectal adenoma.a
Subjects studied GSTM1+ GSTM1 null,
Smoking status cases/controls OR 95% Cl OR 95% Cl
Never smoked 166/209 1.0 0.94 (0.62-1.43)
Ex-smoker 190/217 1.33 (0.88-1.99) 0.94 (0.62-1.43)
Current smoker 90/62 1.73 2.07 (1.14-3.77)
Abbreviations: OR, odds ratio; Cl, confidence interval. "Modified from Lin et al. (64).
metabolized by this cytochrome P450
isozyme are not known.
Another malignancy for v i modifi-
cation ofrisk by metabolic p. orphisms
have been implied is color. .1 cancer.
Rapid acetylators (NAT2) may oe at risk for
colorectal cancers (62), although a study by
Bell et al. (63) in a British population could
not confirm this. Instead, an increased risk
(OR 1.9) was found to be associated with
NAT*J0 allele of the NAT] gene, which
encodes a different acetyltransferase isozyme
(59). However, the increased risk associated
with the NAT] variant allele was most
apparent in NAT2 rapid acetylators (OR
2.8), proposing a gene-to-gene interaction.
Lin et al. (64), on the other hand, studied
possible influence of GSTMI on the risk of
colorectal adenoma. They found that the
risk was increased with smoking, but no
associationi with GSTMI genotype was
found (Table 8).
Conclusions
Susceptibility to certain environmental
cancers due to variation in xenobiotic
metabolism has been demonstrated in
many studies using either phenotyping or
genotyping assays. Some of the studies,
e.g., those on lung cancer, have reported
conflicting results. It is only recently, and
so far in relatively few studies, that influ-
ence ofexposure levels or internal dose has
been examined as a potential modifier of
increased cancer risk linked to genetic sus-
ceptibility. Relationship between dose and
increased metabolic susceptibility to cancer
appears to vary from gene to gene, and
with respect to combinations ofgenotypes
as well as the organ under study (i.e., tissue
specific expression ofthe isozymes). On the
basis ofpresent studies it can be speculated
that in one tissue, increased susceptibility
may become evident at low exposure doses
while in the other this is seen at a high expo-
sure dose only. Present knowledge does not
allow a conclusion as to whether this
hypothesized variation could be related to
the overall capacity ofthe tissue to metabo-
lize xenobiotics. In such a case, high expo-
sure levels might saturate metabolic
capacity by producing large quantities of
reactive intermediates, while at low doses
individual variations in metabolism might
be more significant. Where the increased
risk associated with susceptible genotypes is
observed only at high doses, it could be
that tissue-specific repair mechanisms
would be efficient in protecting against
carcinogenicity at low doses, thus masking
possible influence ofgenetic susceptibility
factors. It is also possible that other than
host-related protective factors might be
involved. For example, different dietary
habits between populations could result in
such a situation.
Another major point to be taken into
consideration is the remarkable variation in
metabolic phenotypes and genotypes
reported for different ethnic or geographic
populations (65-69). When comparing
the influence of genetic susceptibility to
lung cancer between ethnically different
populations, e.g., Caucasians and Japanese
populations, and taking smoking habits
also into account, the results obtained vary
greatly; in large part, this can be attributed
to differences in distribution of the at-risk
alleles in these populations. In a study by
Caporaso et al. (35) in which extensive
metabolizers ofdebrisoquine were found to
be at 4.5- to 10.2-fold risk oflung cancer, a
2-fold difference between whites and
blacks was observed. Epidemiologic studies
have pointed to differences in smoking-
associated lung cancer risk between various
ethnic groups. In a Hawaiian study in
which many confounding factors-e.g.,
smoking habits, pack-years of smoking,
cancer histology, occupation, education,
and dietary factors-were adjusted for,
researchers observed a greater than 2-fold
difference in cancer risk between Japanese
and Hawaiian men (70).
In conclusion, the present data appear
to support suggestions that increased sus-
ceptibility to environmental cancer due to
phenotypic or genotypic variation in car-
cinogen metabolism may be different at
different levels ofexposure, although other
factors, internal or external, are likely to be
involved also.
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